Nova Mentis Assigns Intellectual Property
Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.
NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.
Nova Mentis Life Science Corp. (NMLSF) ha stipulato un accordo di trasferimento di proprietà intellettuale con Ludwig Enterprises Inc. e il Dr. Marvin S. Hausman. NOVA trasferirà la propria proprietà intellettuale relativa al mRNA Neuro Panel e al Serotonin Assay a Ludwig. In cambio, Hausman cancellerà il debito di NOVA di $245,712, e Ludwig emetterà 750,000 azioni comuni ristrette a NOVA. Inoltre, NOVA riceverà un royalty di 10 anni del 2,5% sui ricavi fino a $245,712 e del 5% successivamente dalla commercializzazione della Proprietà.
La fase 2a dello studio clinico di NOVA in Canada per la Sindrome dell'X Fragile ha affrontato sfide nella recluta, con nessun candidato che soddisfi i requisiti di iscrizione. Il Consiglio dell'azienda sta attivamente cercando nuove opportunità commerciali nel settore delle Scienze della Vita per creare valore per gli azionisti.
Nova Mentis Life Science Corp. (NMLSF) ha llegado a un acuerdo de transferencia de propiedad intelectual con Ludwig Enterprises Inc. y el Dr. Marvin S. Hausman. NOVA asignará su propiedad intelectual relacionada con el mRNA Neuro Panel y el Serotonin Assay a Ludwig. A cambio, Hausman perdonará la deuda de NOVA de $245,712, y Ludwig emitirá 750,000 acciones comunes restringidas a NOVA. Además, NOVA recibirá un royalty de 10 años del 2,5% sobre los ingresos hasta $245,712 y del 5% posteriormente de la comercialización de la Propiedad.
El ensayo clínico de fase 2a de NOVA en Canadá para el Síndrome del X Frágil ha enfrentado desafíos en la contratación, sin candidatos que cumplan con los requisitos de inscripción. La Junta de la empresa está buscando activamente nuevas oportunidades comerciales en el sector de Ciencias de la Vida para crear valor para los accionistas.
노바 멘티스 생명과학 주식회사 (NMLSF)는 루드윅 엔터프라이즈와 마빈 S. 하우스만 박사와 지식 재산권 이전 계약을 체결했습니다. NOVA는 mRNA 신경 패널과 세로토닌 분석에 대한 지식 재산권을 루드윅에 양도할 것입니다. 그 대가로 하우스만 박사는 NOVA의 245,712달러 부채를 면제하고, 루드윅은 NOVA에게 750,000주 제한된 보통주를 발행할 것입니다. 추가로, NOVA는 해당 자산의 상용화에서 수익이 245,712달러에 이를 때까지 2.5%의 10년 로열티와 그 이후에는 5%를 받을 것입니다.
NOVA의 캐나다 보건부에서 실시한 X 염색체 증후군 관련 2a 단계 임상 시험은 모집 과정에서 어려움을 겪고 있으며, 현재 등록 요건을 충족하는 후보자가 없습니다. 회사의 이사회는 주주 가치를 창출하기 위해 생명 과학 분야에서 새로운 사업 기회를 적극적으로 모색하고 있습니다.
Nova Mentis Life Science Corp. (NMLSF) a conclu un accord de transfert de propriété intellectuelle avec Ludwig Enterprises Inc. et le Dr. Marvin S. Hausman. NOVA cèdera ses droits de propriété intellectuelle concernant le mRNA Neuro Panel et le Serotonin Assay à Ludwig. En échange, Hausman renoncera à la dette de NOVA de 245 712 $ et Ludwig émettra 750 000 actions ordinaires restreintes à NOVA. De plus, NOVA recevra une redevance de 10 ans de 2,5 % sur les revenus jusqu'à 245 712 $ et de 5 % par la suite issus de la commercialisation du bien.
L'essai clinique de phase 2a de NOVA au Canada pour le syndrome de l'X fragile a rencontré des difficultés de recrutement, aucun candidat ne répondant aux critères d'inscription. Le conseil d'administration de l'entreprise est activement à la recherche de nouvelles opportunités commerciales dans le secteur des sciences de la vie pour créer de la valeur pour les actionnaires.
Nova Mentis Life Science Corp. (NMLSF) hat einen Übertragungsvertrag für geistiges Eigentum mit Ludwig Enterprises Inc. und Dr. Marvin S. Hausman abgeschlossen. NOVA wird sein geistiges Eigentum bezüglich des mRNA Neuro Panels und des Serotonin Assays an Ludwig abtreten. Im Gegenzug wird Hausman die Schulden von NOVA in Höhe von 245.712 USD erlassen, und Ludwig wird 750.000 beschränkte Stammaktien an NOVA ausgeben. Darüber hinaus wird NOVA eine 10-jährige Lizenzgebühr von 2,5% auf Einnahmen bis zu 245.712 USD und 5% danach aus der Kommerzialisierung des Eigentums erhalten.
Die Phase 2a klinische Studie von NOVA in Kanada zur Fragilen X-Syndrom hat Rekrutierungsprobleme gehabt, da keine Kandidaten die Einschlusskriterien erfüllen. Der Vorstand des Unternehmens sucht aktiv nach neuen Geschäftsmöglichkeiten im Bereich der Lebenswissenschaften, um den Shareholder-Wert zu steigern.
- Debt forgiveness of $245,712
- Acquisition of 750,000 restricted shares of Ludwig Enterprises
- 10-year royalty agreement on commercialization of assigned intellectual property
- Active pursuit of new business opportunities in Life Sciences sector
- Assignment of valuable intellectual property to Ludwig Enterprises
- Challenges in recruiting participants for Phase 2a clinical trial
- No enrolled participants in the Fragile X Syndrome study
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") is pleased to announce it has entered into an intellectual property conveyance agreement (the "Agreement") with Ludwig Enterprises Inc. ("LUDG") and Dr. Marvin S. Hausman ("Hausman"), CEO of Ludwig, pursuant to which the Company shall assign to Ludwig all of its intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay, along with any and all data accumulated testing these assays (the "Property").
Under the terms of the Agreement, in consideration of the assignment of the Property, Hausman shall forgive the Company on a total of USD
Corporate Update
Regarding the Company's Health Canada Phase 2a clinical trial "An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients" - the recruitment portion of the trial has proven to be very challenging. Together with its' Contract Research Organization partner KGK Science, over 20 individuals have been vetted for enrollment but unfortunately none have met the stringent requirements for enrollment.
Coupled with the challenges the psychedelic sector has and is going through, NOVA's Board is actively seeking suitable business opportunities that create shareholder value and compliment the Company's current CSE industry listing - Life Sciences.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company, developing psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., (OTC Pink: LUDG) a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to prevent chronic inflammation, the causative agent of illnesses™ such as cancer and heart disease, which are responsible for more than
Ludwig has embarked on a plan to reshape the Company as it nears its launch of Revealia™.
A key initiative is changing the corporate name to "Revealia™, Inc." Following regulatory approvals, the new company name and a new ticker to match it would be in place. Revealia™ is also the name of the company's breast cancer screening product.
The Company intends to apply with OTCMarkets to begin trading on the OTCQB, a first step in its longer-range plan of seeking a higher listing, such as NASDAQ or CBOE.
For more information please visit: http://www.ludwigent.com.
For further information on the Company, please visit www.novamentis.ca or email info@novamentis.ca.
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
Contact Ludwig at:
Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CEO
marvin@ludwigent.com
www.ludwigent.com
Twitter: @LUDG_inc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221216
FAQ
What intellectual property did Nova Mentis (NMLSF) assign to Ludwig Enterprises?
What did Nova Mentis (NMLSF) receive in exchange for the intellectual property assignment?
What challenges is Nova Mentis (NMLSF) facing with its Phase 2a clinical trial?
What is Nova Mentis (NMLSF) doing to address its business challenges?
